ClinicalTrials.gg
RecruitingNCT02333604CERUpdated Oct 29, 2026

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

An observational study in Neoplasms, Cancer and Caregiver, sponsored by Cancer Support Community, Research and Training Institute, Philadelphia. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Cancer Support Community, Research and Training Institute, Philadelphia · Observational

How we know

From the registry’s dates

  • Started Mar 2013; still recruiting 13 years 8 months later.
Updated Oct 29, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
15,000
Ages
18 Years and older
Sex
All
01

Study summary

The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surveys are designed based on input from advisor experts, including patients and caregivers, and focus on the social, emotional, physical, financial and decision-making experiences of those who have been diagnosed with cancer and their caregivers. Findings contribute toward enhancing care for patients, survivors and caregivers via programming and policy initiatives.

Read the detailed description

The aims of the Registry are to: 1) better understand the psychosocial experiences and needs of people who have been impacted by cancer, including patients, survivors and caregivers; 2) inform the research community, healthcare providers, patient advocates and policy makers around gaps in care and the psychosocial challenges of people affected by cancer; 3) use the findings to develop and disseminate tailored (data-guided) programs and services that will address the emotional and social needs and ultimately improve the long-term quality of life of people affected by cancer; 4) link registrants to cancer related resources and programs via an online, modifiable platform; and 5) provide collaborating sites (e.g., hospitals/health networks/CSC affiliates) with aggregated reports on quality and needs of members or customers to enhance or improve quality of care.

Findings from the Registry are disseminated online at https://www.cancersupportcommunity.org/sites/default/files/file/2020-07/CSC_Registry_Report_June_2020.pdf

02

Conditions studied

  • Neoplasms
  • Cancer
  • Caregiver

Keywords

  • cancer
  • cancer survivorship
  • psychosocial needs
  • cancer experience
  • acute myelogenous leukemia
  • breast cancer
  • breast cancer, metastatic
  • chronic lymphocytic leukemia
  • chronic myeloid leukemia
  • liver cancer
  • lung cancer
  • melanoma
  • multiple myeloma
  • myelodysplastic syndrome
  • ovarian cancer
  • prostate cancer
  • stomach cancer
  • bladder cancer
  • colorectal cancer
  • patient insights
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 15,000 is above the median of 200 across 2,644 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Cancer Support Community, Research and Training Institute, Philadelphia is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Any individual who has received a cancer diagnosis or has been a family caregiver or informal caregiver for someone diagnosed with cancer

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have received a cancer diagnosis or have been a family caregiver or informal caregiver (i.e., a relative or friend) for someone diagnosed with cancer
  • Live in United States, a US territory, or Canada
  • Able to read and understand English

Exclusion criteria

Exclusion criteria:

  • None
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
15,000 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Self-reported quality of life measures

    Participant self-reported symptoms and functioning will be measured using the Patient-Reported Outcomes Measurement Information System-Preference Score (PROMIS-Pr). Five domains assess symptoms with higher scores corresponding to worse symptomology (Depression; Anxiety; Pain Interference; Fatigue; Sleep Disturbance) and three assess function with lower scores corresponding to worse functioning (Physical Function; Ability to Participate in Social Roles and Activities; Cognitive Function). Participants rate each item with reference to the past seven days; function scales have no timeframe specified. Scale scores are converted to standardized T scores (mean = 50, SD = 10); normative reference groups are the U.S. general population, except Sleep Disturbance, where comparisons are to a mix of the U.S. population and people with chronic illness.

    Time frame: 7 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — IPD is not available at this time. Data in aggregate is shared with recruitment partners.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2013 (actual). Primary completion is estimated for Jan 2035, 262 months after the start.

Of 1,099 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 262 months is above that.

Counting every sponsor, half of 1,247 studies reached it within 58 months; a quarter within 24 and three quarters within 210.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2015
First posted
Jan 7, 2015
StartActual
Mar 2013
Primary completionEst.
Jan 2035
CompletionEst.
Dec 2035
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: e•••@cancersupportcommunity.org · •••9709→o•••@cancersupportcommunity.org · •••9709; k•••@cancersupportcommunity.org→j•••@cancersupportcommunity.org · •••9709. See the current contact
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Contact Study contact changed: e•••@cancersupportcommunity.org · •••9709→o•••@cancersupportcommunity.org · •••9709; k•••@cancersupportcommunity.org→j•••@cancersupportcommunity.org · •••9709. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02333604
Lead sponsor
Cancer Support Community, Research and Training Institute, Philadelphia
Responsible party
Erica E. Fortune (Vice President, Research, Cancer Support Community, Cancer Support Community, Research and Training Institute, Philadelphia) — Principal investigator
First posted
Jan 7, 2015
Start date
Mar 2013
Primary completion
Jan 2035 (estimated)
Completion
Dec 2035 (estimated)
Last update
Oct 29, 2026

Study contacts

Olajide Fadare, PhD
Contact
ofadare@cancersupportcommunity.org
202.659.9709 ext. 10105
Jhenitza Raygoza, MPH
Contact
jraygoza@cancersupportcommunity.org
202.659.9709 ext. 3011
Erica E. Fortune, PhD
principal investigator · Cancer Support Community

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion